

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see [Authors & Referees](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- | | | |
|-------------------------------------|-------------------------------------|--|
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | The statistical test(s) used AND whether they are one- or two-sided
<i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i> |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | A description of all covariates tested |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
<i>Give P values as exact values whenever suitable.</i> |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated |

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection

Not applicable.

Data analysis

Statistic analysis were performed by GraphPad Prism software. Flowjo was used to analyze flow cytometry data. Organoid size was analyzed by image J software described in methods section.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

Source data of this study was provided with the paper for supplementary data.
Analyzed RNAseq data was provided in supplementary data.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	Detail of sample size of all experiments are provided in figure legends.
Data exclusions	No data was excluded from the analysis.
Replication	All experiments were repeated at least twice.
Randomization	All mice were randomized before experiments.
Blinding	Blinding was not performed in this study

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology
<input type="checkbox"/>	<input checked="" type="checkbox"/> Animals and other organisms
<input checked="" type="checkbox"/>	<input type="checkbox"/> Human research participants
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data

Methods

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input type="checkbox"/>	<input checked="" type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

Antibodies

Antibodies used	anti-Ki-67-PE (#12-5698-82, invitrogen, 1:200) and anti-EpCAM-APC (#17-5791-82, invitrogen, 1:200) were used for flow cytometry analysis in 1:200 dilution. anti-acetyl-histone H3 (#06-599, EMD Millipore) was used for ChIP assay. anti-GFP (#GFP-1020, Aves, 1:1000), anti-Ki-67 (#ab15580, abcam, 1:500), anti-BrdU (#ab6326, abcam, 1:250), anti-beta catenin (#8814, Cell signaling, 1:500), Alexa fluor 488 conjugated anti-rabbit IgG (#A21206, Invitrogen, 1:1000), Alexa fluor 647 conjugated anti-rat IgG (#A21247, Invitrogen, 1:1000) and Alexa fluor 647 conjugated anti-chicken IgY (#A21449, Invitrogen, 1:1000) were used for immunofluorescence staining.
Validation	All antibody are commercially available and were validated by provider.

Eukaryotic cell lines

Policy information about [cell lines](#)

Cell line source(s)	HT-29 cell was provided by Dr. Merlin. SKCO-15 cell was provided by Dr. Nusrat.
Authentication	No authentication was performed.
Mycoplasma contamination	All all cells were negative for mycoplasma contamination.
Commonly misidentified lines (See ICLAC register)	No commonly misidentified cell line were used.

Animals and other organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research

Laboratory animals	C57BL/6, Lgr5-EGFP-IRES-creERT2 and Myd88 ^{-/-} mice were purchased from the Jackson Laboratory. TLR4 ^{-/-} mice was provided by Dr. Gewirtz.
Wild animals	Not applicable.
Field-collected samples	Not applicable.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Flow Cytometry

Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation

Samples were prepared as described in methods section.

Instrument

BECKMAN COULTER, CytoFLEX Flow Cytometer

Software

CytoExpert for data collection. Flowjo software version 10 for data analysis.

Cell population abundance

>10,000 cells were analyzed. No sorting experiment in this study.

Gating strategy

All gating strategy started by FSC and SSC area, and live cells.

- Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.